Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML: single center report of the ENACT trial in Lebanon.

Authors :: Otrock ZK
Mahfouz RA
Fahed Z
Farhat FS
Ziade A
Nasr F
Kassem N
Abboud MR
Source :: International journal of hematology [Int J Hematol] 2012 Oct; Vol. 96 (4), pp. 521-4. Date of Electronic Publication: 2012 Sep 09.
Publication Year :: 2012

Subjects :: Antineoplastic Agents administration & dosage
Benzamides
Drug Resistance, Neoplasm
Humans
Imatinib Mesylate
Piperazines administration & dosage
Protein Kinase Inhibitors administration & dosage
Pyrimidines administration & dosage
Treatment Outcome
Antineoplastic Agents therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy
Piperazines therapeutic use
Protein Kinase Inhibitors therapeutic use
Pyrimidines therapeutic use

Full Text Access

Tools